Citius Pharmaceuticals merged its oncology subsidiary with TenX Keane Acquisition to form Citius Oncology, set to go public on Nasdaq as CTOR. The new company will focus on developing targeted oncology therapies, starting with LYMPHIR, approved by the FDA for CTCL treatment.